Quarterly report pursuant to Section 13 or 15(d)

Business Combination - Narrative (Details)

v3.20.2
Business Combination - Narrative (Details)
6 Months Ended 18 Months Ended
Apr. 01, 2020
USD ($)
Jul. 23, 2019
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
acquisition
Business Acquisition [Line Items]          
Number of acquisitions | acquisition         2
Acquisition related costs         $ 0
Cash payments for acquisition     $ 15,140,000 $ 0  
Icagen          
Business Acquisition [Line Items]          
Consideration transferred in acquisition $ 19,900,000        
Cash payments for acquisition 15,100,000        
Contingent earn-out payment 25,000,000.0        
Fair value of contingent earn-out payment 4,800,000        
Tangible assets acquired 1,800,000        
Liabilities assumed (800,000)        
Finite-lived intangible assets acquired 12,800,000        
Deferred revenue acquired (3,700,000)        
Deferred tax assets acquired 800,000        
Goodwill acquired $ 9,000,000.0        
Weighted-average estimated useful life of finite-lived intangible assets acquired 9 years 8 months 12 days        
Icagen | Customer Relationships          
Business Acquisition [Line Items]          
Finite-lived intangible assets acquired $ 11,100,000        
Discount rate used to value intangible assets acquired (as a percent) 17.00%        
Weighted-average estimated useful life of finite-lived intangible assets acquired 9 years 7 months 6 days        
Icagen | Core Technology          
Business Acquisition [Line Items]          
Finite-lived intangible assets acquired $ 1,700,000        
Discount rate used to value intangible assets acquired (as a percent) 17.00%        
Weighted-average estimated useful life of finite-lived intangible assets acquired 10 years        
Ab Initio Biotherapeutics, Inc.          
Business Acquisition [Line Items]          
Consideration transferred in acquisition   $ 12,000,000.0      
Cash payments for acquisition   11,840,000      
Tangible assets acquired   30,000.00      
Liabilities assumed   (80,000.00)      
Goodwill acquired   6,300,000      
Cash holdback for potential indemnification claims   150,000      
Deferred tax liability acquired in connection with the acquired intangibles   (1,600,000)      
Ab Initio Biotherapeutics, Inc. | Core Technology          
Business Acquisition [Line Items]          
Finite-lived intangible assets acquired   $ 7,400,000      
Discount rate used to value intangible assets acquired (as a percent)   12.00%      
Weighted-average estimated useful life of finite-lived intangible assets acquired   20 years